Biotech | November 18, 2021
Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The centre has an initial capacity of 500 FTEs
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Acute therapies continue to report strong growth compared to chronic ones.
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The initiative will create an integrated network of Critical Care Units (CCUs) across the Apollo Hospitals network but also in partnership with non-Apollo units in India and overseas
The kit preserves viral nucleic acids in a non-hazardous stabilization solution that inactivates common respiratory viruses for safer sample collection
Subscribe To Our Newsletter & Stay Updated
